Due to the COVID-19 pandemic the conducting of clinical trial operations are becoming more adaptable, accelerating the adoption of technology that integrates remote monitoring applications. The impact of the pandemic has changed the way Vivalink and other medical wearable companies have deployed their remote patient monitoring strategies for both hybrid and decentralized trials. Some of the most notable advantages of this strategic plan for RPM enabled trials include: patient centricity, trial access, adaptability relating to scheduling, reduced burden to the site and patient, and more. The potential obstac;es that come from this new way of thinking about clinical trials include: patient access to the internet, matching the right biosensor technology with the right digital endpoints, scalability, increased cost of new technologies and software/application programming interface updates and installations, and more. Learn more about these new technologies and strategies that are being incorporated by wearable biosensors in clinical and hybrid patient monitoring trials.